Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potassium Supplementation in ADHD
NCT03563573Phase 2Unknown
- Sponsor
- AlkaliDx
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Potassium in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by AlkaliDx. Primary endpoint: Prevalence of lidocaine ineffectiveness in those with ADHD. Status: unknown.
02
Drugs
Potassium
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03563573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563573.